|
Season’s greetings from The Mark Foundation for Cancer Research!
As we close out 2024, we’re proud to reflect on a year of progress in the fight against cancer. Read on to learn about what we’ve achieved and our plans for 2025.
|
|
|
Investing in Early Career Scientists
|
|
 |
We presented five remarkable scientists with Emerging Leader Awards in 2024. These three-year grants, worth a total of $750,000, help early-career researchers pursue their boldest, riskiest ideas. Learn more about their research. We’ll announce our 2025 cohort in January —stay tuned!
|
|
|
|
|
|
|
|
|
|
|
|
|
Making Bold Bets on Promising Reseach
|
|
In 2024, we awarded three ASPIRE II Awards to researchers spanning four countries:
|
|
- Shom Goel MD, PhD, Peter MacCallum Cancer Centre (Australia)
- Erik Sahai, PhD, and Helen Byrne, DPhil, Francis Crick Institute and University of Oxford (United Kingdom)
- Denes Hnisz, PhD, and Xavier Salvatella, PhD,Max Planck Institute for Molecular Genetics (Germany) and Institute for Research in Biomedicine (Spain)
|
|
This follow-on funding allows awardees to advance work begun through previous ASPIRE grants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supporting Tomorrow’s Leaders
|
|
|
We supported the next generation of cancer researchers by awarding nine Momentum Fellowships to talented postdoctoral researchers in four countries to help them accelerate innovative projects.
Learn more about their research.
|
|
|
|
|
|
|
|
|
|
|
|
|
Driving Multidisciplinary Science
|
|
|
 |
FLASH radiation equipment at the UPenn Center
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our grantees have published a remarkable 204 peer-reviewed scientific papers so far in 2024, reflecting the breadth and quality of their work. Each quarter, we share a list of high-impact highlights —view our roundups from the first, second, and third quarters and look out for our fourth-quarter list in January.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalyzing New Collaborations
|
|
 |
Precision Targeting of the Tumor Ecosystem Workshop
|
|
|
We held two interdisciplinary workshops this year, bringing together global leaders around emerging trends in cancer research. Targeted follow-on funding opportunities are allowing participants to pursue new collaborations launched at the workshops.
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
No Stone Unturned Workshop
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tackling Grand Challenges
|
|
In March, we committed to funding our third
Cancer Grand Challenges team. MATCHMAKERS, which we support alongside Cancer Research UK and the National Cancer Institute, is creating tools to predict T cell antigen specificity and unlock more more targeted and effective immunotherapies. The other two Mark Foundation-funded teams, SPECIFICANCER and NexTGen, also reported notable scientific progress in 2024.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Partnering to Support High-Impact Research
|
|
We regularly partner with other foundations to support individuals and projects at the cutting edge of cancer research. In 2024, those efforts included:
|
|
|
|
Building Our Network of Experts
|
|
|
This year, we were honored to announce the appointment of four new Mark Foundation advisors: Sarah-Jane Dawson, Johanna Joyce, and Charles Swanton, who joined our Scientific Advisory Committee; and Wendy Young, who was appointed to the Industry Advisory Committee.
Read more about their backgrounds.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025 promises to be a busy and impactful year for The Mark Foundation.
In January and February, we’ll announce the recipients of our next Emerging Leader Award, Endeavor Award, and Mark Foundation Center grants and share news about exciting new partnerships. Later in the year, we’ll present new ASPIRE and Drug Discovery Awards.
This April, we will gather in New York City for our Scientific Symposium, where we'll hear updates from our grantees. Throughout the year, we also look forward to convening, learning, and collaborating with many of you at upcoming workshops, conferences, and meetings around the world.
We look forward to another year working together to transform the prevention, diagnosis, and treatment of cancer.
|
|
|
|
|
Planning your year-end giving? 100% of your tax-deductible contribution to The Mark Foundation is directed toward supporting world class research that will accelerate innovations from the bench to the bedside.
|
|
|
Help spread the word about The Mark Foundation!
Please share this email with others in your network and follow us on social media.
|
|
|
|
|
|